Suspected Biphasic Anaphylaxis Following the First Known Dose of Tirzepatide: A Case Report and Brief Review of Reported Hypersensitivity Reactions
- Design
- Pharmacovigilance · Unknown outcome
- Match to healthy normal-weight adults aged 55–75
- Population unclear[Auto] Population characteristics not extractable from abstract (age/BMI not reported in abstract). Needs manual review.
- Could weight loss explain it?
- Unknown[Auto] Not addressed in abstract.
- Study tier
- Study tier 4[Auto] Hypothesis-generating design (auto-provisional).
- Assessment
- Version 1 · automatic, not yet reviewed by a person · Sep 13, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
[Auto, unreviewed; last sentences of abstract] Acute and baseline serum tryptase levels were unavailable, and validated allergy testing for tirzepatide was not performed; therefore, the underlying immunological mechanism could not be established. This case highlights the importance of early recognition and prompt treatment of tirzepatide-associated anaphylaxis, as well as continued pharmacovigilance and detailed reporting of severe hypersensitivity reactions.
01Findings
What the study reported
- Drugs
- Tirzepatide
- Route
- subcutaneous
- Primary outcome
- Not extracted
- Effect
- Not extracted
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
- Diabetes status
- diabetes mentioned
Study quality details
- Study design
- Pharmacovigilance analysis
- Sample size
- not extracted
- Randomization
- no
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- not stated
- Outcome type
- unknown
- Replication
- not assessed (auto)
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- UNKNOWN
- Statistical precision
- not extracted
- Risk of bias
- not assessed (auto)
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- None identified
- Sponsor role
- not reported in abstract
- Author conflicts
- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist increasingly used for type 2 diabetes mellitus and chronic weight management. Although generally well tolerated, serious systemic hypersensitivity reactions may occur. We report a 37-year-old woman who developed anaphylaxis shortly after administering her first known subcutaneous dose of tirzepatide. She presented with facial and periorbital angioedema, nasal congestion, generalized urticaria, bronchospasm, hypoxemia, and hypotension. She was treated with intravenous fluids, nebulized bronchodilators, and two doses of intramuscular epinephrine, resulting in complete clinical resolution. Approximately one hour later, she developed recurrent generalized urticaria, facial angioedema, and chest tightness without further exposure to the suspected trigger. Although no objective respiratory or hemodynamic compromise was documented during the recurrent episode, the recurrence was considered suggestive of a possible biphasic reaction. Her symptoms resolved following treatment with intravenous hydrocortisone and chlorphenamine. Acute and baseline serum tryptase levels were unavailable, and validated allergy testing for tirzepatide was not performed; therefore, the underlying immunological mechanism could not be established. This case highlights the importance of early recognition and prompt treatment of tirzepatide-associated anaphylaxis, as well as continued pharmacovigilance and detailed reporting of severe hypersensitivity reactions.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 13, 2026 | 42694337 first ingestion |